Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 7

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 7
---
 any future clinical trials of our drug candidates is critical to our success. The timing of our
clinical trials depends on the speed at which we can recruit patients to participate in testing our drug candidates. Patients may be unwilling
to participate in any future clinical trials because of negative publicity from adverse events in the biotechnology industry. Patients
could be unavailable for other reasons, including competitive clinical trials for similar patient populations, and the timeline for recruiting
patients, conducting trials and obtaining regulatory approval of potential products may be delayed. If we have difficulty enrolling a
sufficient number of patients to conduct any future clinical trials as planned, we may need to delay, limit or discontinue those clinical
trials. Clinical trial delays could result in increased costs, slower product development, setbacks in testing the safety and effectiveness
of our technology or discontinuation of the clinical trials altogether.

Any failure to implement our business strategy could negatively
impact our business, financial condition and results of operations

The development and commercialization of our drug
candidates is subject to many risks, including:

  additional clinical or pre-clinical trials may be required beyond what we currently expect;  
 ───────────────────────────────────────────────────────────────────────────────────────────────

  regulatory authorities may disagree with our interpretation of data from our preclinical studies and clinical studies or may require that we conduct additional studies;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  regulatory authorities may disagree with our proposed design of future clinical trials;  
 ───────────────────────────────────────────────────────────────────────────────────────────

  regulatory authorities may delay approval of our drug candidates, thus preventing milestone payments from our collaboration partners;  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  regulatory authorities may not accept data generated at our clinical study sites. In particular, we are conducting, and will conduct, some of our clinical trials outside the United States. The ...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  we may be unable to obtain and maintain regulatory approval of our drug candidate in any jurisdiction;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────

  the prevalence and severity of any side effects of any drug candidate could delay or prevent commercialization, limit the indications for any approved drug candidate, require the establishment ...